Please enable Javascript
Blood Cancers Today Staff Writers
Staff Writers
Articles by Blood Cancers Today Staff Writers
FDA Grants Accelerated Approval to Ponatinib in Ph+ ALL
Blood Cancers Today Staff Writers
Acute Lymphoblastic Leukemia
|
March 19, 2024
Efficacy was based on the MRD-negative CR rate at the end of induction.
Read More
BLA for Denileukin Diftitox in CTCL Resubmitted to FDA
Blood Cancers Today Staff Writers
T-Cell Lymphoma
|
March 18, 2024
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
Read More
ODAC Panel Votes in Favor of Supplemental FDA Application for Ide-Cel
Blood Cancers Today Staff Writers
Myeloma
|
March 18, 2024
The 11-member panel of independent experts voted eight in favor and three against.
Read More
Cilta-Cel Receives Positive Recommendation for Updated Indication in Myeloma
Blood Cancers Today Staff Writers
Myeloma
|
March 15, 2024
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
Read More
FDA Advisory Committee Supports Benefit of Imetelstat for Anemia in Lower-Risk MDS
Blood Cancers Today Staff Writers
Myelodysplastic Syndromes
|
March 14, 2024
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
Read More
FDA Approves Inotuzumab Ozogamicin in Pediatric B-Cell Precursor ALL
Blood Cancers Today Staff Writers
Acute Lymphoblastic Leukemia
|
March 6, 2024
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
Read More
CHMP Issues Positive Opinion for Luspatercept in Anemia Due to MDS
Blood Cancers Today Staff Writers
Myelodysplastic Syndromes
|
February 27, 2024
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Read More
FDA Approves Biweekly Dosing for Teclistamab in Relapsed or Refractory Myeloma
Blood Cancers Today Staff Writers
Myeloma
|
February 21, 2024
The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.
Read More
Selinexor Added to China’s National Reimbursement Drug List
Blood Cancers Today Staff Writers
Print
|
February 8, 2024
Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.
Read More
FDA Grants Breakthrough Device Designation for Multicancer Early Detection Solution
Blood Cancers Today Staff Writers
Print
|
February 8, 2024
CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.
Read More
China’s NMPA Accepts sBLA for Relma-Cel Injection
Blood Cancers Today Staff Writers
Print
|
February 8, 2024
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.
Read More
FDA Places Magrolimab Trials on Full Clinical Hold; AML ENHANCE-3 Trial Discontinued
Blood Cancers Today Staff Writers
Acute Myeloid Leukemia
|
February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Read More
CR&T Lifetime Achievement Award Recognizes Lymphoma Researcher
Blood Cancers Today Staff Writers
Indolent B-Cell Lymphoma
|
February 2, 2024
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
Read More
Sonrotoclax Overcomes Venetoclax Resistance in Preclinical Hematologic Malignancy Models
Blood Cancers Today Staff Writers
Chronic Lymphocytic Leukemia
|
January 16, 2024
The therapy is currently under investigation in multiple clinical trials.
Read More
Baseline Immunologic State Affects CAR-T Cell Response in LBCL
Blood Cancers Today Staff Writers
Aggressive B-Cell Lymphoma
|
February 2, 2024
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
Read More
Real-World Data Show High Rate of Second Cancers After Polycythemia Vera Diagnosis
Blood Cancers Today Staff Writers
Polycythemia Vera
|
February 2, 2024
The retrospective study used data on 105 million U.S. patients with linked medical and prescription claims from 2007 to 2019.
Read More
Load More